06 Dec 2024
EMA/276856/2024
Human Medicines Division

# 3-year rolling work plan for the Biosimilar Medicinal Products Working Party

| | |
|---|---|
| Name of Working Party: | Biosimilar Medicinal products Working Party (BMWP) |
| Chairperson: | René Anour |
| Vice chair: | Niklas Ekman |

Work plan period: January 2025 – December 2027

**Official address** Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
**Address for visits and deliveries** Refer to www.ema.europa.eu/how-to-find-us
**Send us a question** Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

# Table of contents

# 1. Strategic goals

### *1.1. Short-term strategic goals*

- Provide support to SAWP and CHMP on aspects pertaining to procedures for biosimilars, with the aim to prepare SAWP/CHMP opinions (peer reviewed/consensus driven opinions) on biosimilarity during Scientific Advice and Marketing Authorisation Application procedures upon request by SAWP / CHMP.
- Continue to improve efficiency of internal process interactions with SAWP with a risk-based focus, e.g., "tailored" regulatory pathway.
- Progress development of EU and international guidelines on biosimilars and identify/prioritise new guidance topics as relevant, e.g., reduced clinical efficacy studies. Progress draft guidelines and provide support to training activities on implementation of priority guidelines.
- Support and enhance the development of biosimilar products and further clarify the regulatory expectations in manufacturing e.g., if / when statistical assessment of critical quality attributes (CQAs) should be performed as part of the comparability exercise and the evolution of multisource biologicals/biosimilars.
- Provide support to EU Network and public health organisations in activities involving scientific and regulatory aspects of biosimilar medicinal products.
- Collaboration with the European Regulatory Network, advance international regulators and stakeholder interactions: academia, trade associations, interested parties, etc.
- Harmonise communication / procedural outputs for biosimilars, e.g., assessment reports, Product Information and European Public Assessment Reports (EPARs).
- Consider the potential impact of proposed changes to the EU pharmaceutical legislation for biosimilars, e.g., definitions, bio-hybrid pathway, removal of risk management plan

### *1.2. Long-term strategic goals*

The long-term strategic priorities for the BMWP, with reference to the European medicines agencies network strategy (EMANS) / European Medicines Regulatory Network (EMRN) and Regulatory Science Strategy 2025 are as follows:

- Work to strengthen the availability of medicines to protect the health of European citizens, ensuring that quality, safe and effective biological medicines are available to EU citizens.
- Leverage EMA's extensive experience in approving biosimilars to provide state of the art guidance on developing Biosimilar Medicines in Europe and share experience globally.
- Continue the refinement and efficiency of biosimilars regulatory processes, e.g., adapting the clinical part of the development to the latest scientific knowledge concerning the comparability assessment.
- Prepare and contribute to Questions and Answers documents to facilitate understanding of new and existing guidelines.
- Anticipate evolution in regulatory science and develop guidance for product classes for which Biosimilars may be developed in future. Gain understanding of industry pipeline activities.
- Support and enhance efficient scientific advice procedures by development of Guidance documents for internal or external reference / stakeholders, as required.

- Through HMA interaction, promote the availability and support uptake of biosimilars in healthcare systems with strategic communication campaigns to healthcare providers and patient organisations to reinforce trust and confidence.

# 2. Tactical goals

### *2.1. Guidance activities*

The below guideline activities reflect the strategic goals listed above, in particular to refine and improve efficiency of biosimilars regulatory processes and to consolidate learnings/support knowledge management for strategic topic areas.

#### (A) Activities ongoing/to be finalised in 2025

1. Continue activities related to the Reflection Paper on a tailored clinical approach, with multidisciplinary input from EU Network and external stakeholders, with draft for external consultation by 2Q 2025. A workshop to progress the drafting of the Reflection Paper will be organised in September 2025.
2. Implement revised biosimilar CHMP assessment report template to standardise statements in EPARs, improving consistency / detail of information for Health Care Professionals regarding the comparability exercise.
3. Review progress with implementation of a revised Tailored Scientific Advice process for biosimilars development and further clarify, based on experience.

#### (B) Activities to be started in 2025

Consider revision of general biosimilar guidelines, in collaboration with BWP. In particular:

- Guideline on similar biological medicinal products;
- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: nonclinical and clinical issues EMA/CHMP/BMWP/403543/2010

#### (C) Activities to be started in 2026-2027

- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues.
- Revision of the guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues EMA/CHMP/BMWP/403543/2010;
- Monitor the application of non-EEA sourced reference medicinal product in clinical studies;
- Develop regulatory approaches in the analytical comparability, e.g., related to identification and assessment of quality attributes.

Further guideline activities (new guidance/revisions) may arise in relation to the implementation of new/revised pharmaceutical legislation.

**(D) Ongoing BMWP support to non-EU guidelines**

- Contribute to IPRP activities related to biosimilars development;
- Contribute to WHO activities related to biosimilars development.

### *2.2. Training and workshop activities*

Continue training of EU quality assessors on a regular basis.

- For each new biosimilar guidance and other revised guidance;
- Maintain awareness of issues arising from product-specific discussions;
- Support the network e.g., Heads of Medicines Agencies (HMA) on communication materials related to interchangeability;
- Enhance training of non-EU regulators in the evaluation of biosimilars.

### *2.3. Communication and Stakeholder activities*

#### 2.3.1. European level

Continue to engage effectively with industry to gain external perspective on regulatory science needs. An interested parties meeting can be considered and complemented by ad hoc meetings in smaller groups as needed.

Promote the availability and support uptake of biosimilars in healthcare systems.

Provide support for stakeholder meeting for exchange of information/experiences:

- Collaborate with HMA Biosimilar Group (e.g. national toolkits), to further develop scientific publications +/or strategic communication campaigns to healthcare providers and patient organisations to reinforce trust and confidence;
- Work with healthcare professionals and patients to facilitate understanding of the science behind the development and regulation of these medicines;
- Improve coordination of information and actions, including implementation of best practices, both for EU regulatory authorities, stakeholders and international partners.

#### 2.3.2. International level

International cluster meetings: advance global information sharing and harmonisation in biosimilar development requirements, identify gaps between different legislators and how these impact product approvals in EU.

Support IPRP-BWP on reduction of clinical data requirements: Comparative Efficacy Studies (CES) and outcomes following workshop (e.g., white paper).

Support international harmonisation initiatives in relevant international fora, including WHO and relevant guideline activities.

### *2.4. Multidisciplinary collaboration*

Maintain or strengthen as relevant, the ongoing collaboration with other working parties (WP) and groups, for example on procedural support and guidance, e.g., Scientific Advice (SAWP), Biologics (BWP), Methodology (MWP) working parties.

# 3. Operational goals

### *3.1. Pre-submission activities*

- Recommendation to CHMP and SAWP on specific applications for scientific advice and protocol assistance (focus: new biosimilar substances and non-routine procedures/aspects);
- Support BWP on provision of Scientific Advice for the in-depth review of quality data for similar biological medicinal products upon request of the SAWP.

### *3.2. Evaluation and supervision activities*

- Recommendation to CHMP and SAWP on applications for marketing authorisations and other procedures as appropriate (focus: new active substances and non-routine procedures/aspects).
- Support to public health activities related to similar biological medicinal products.

# 4. List of Abbreviations

| Abbreviation[1] | |
|---|---|
| BMWP | (EMA CHMP) Biosimilar Medicinal Products Working Party |
| BWP | (EMA CHMP) Biologics Working Party |
| CES | Comparative Efficacy Studies |
| CHMP | (EMA) Committee for Medicinal Products for Human Use |
| CQA | Critical Quality Attribute |
| EMRN | European Medicines Regulatory Network (see EMRN) |
| EMANS | European medicines agencies network strategy (EMANS) |
| EPAR | European public assessment report (see EPAR) |
| HCP(s) | Healthcare Professional(s) |
| HMA | Heads of Medicines Agencies (see HMA) |
| IPRP | International Pharmaceutical Regulators Programme (see IPRP) |
| MWP | (EMA CHMP) Methodology Working Party (see MWP) |
| RSS | Regulatory Science Strategy (see RSS) |
| SAWP | (EMA CHMP) Scientific Advice Working Party (see SAWP) |
| WHO | World Health Organization |
| WP | Working party (see Working parties and domains) |

[1] Acronyms are abbreviations that can be pronounced as a word (e.g., 'CAT') whereas initialisms are abbreviations for which each letter is pronounced separately (as in 'SME')